- PANFACIAL VOLUMIZATION
63-year-old ballet dancer
- PANFACIAL REJUVENATION
By Treatment Area
- Multiple approaches/techniques may be demonstrated for the treatment areas listed below
- Oral Commissures/Marionettes
- Prejowl Sulcus/Jaw
- Advanced Area
- Advanced Area
- Avoiding & Managing Complications
- TOXIN TECHNIQUES
By Treatment Area
- CLINICAL CONSIDERATIONS
At the conclusion of this activity, participants should be better able to:
• Interpret the basics of facial anatomy in order to assess the anatomical changes related to the aging face.
• Perform comprehensive patient assessments and manage patient expectations in order to increase patient satisfaction and enhance outcomes.
• Apply the three-dimensional concept of facial volumization and targeting facial zones, rather than specific treatment areas, in order to optimize aesthetic outcomes.
• Recognize the differences among the various HA-based dermal fillers in order to assist in the appropriate selection and placement of these agents.
• Demonstrate protocols and techniques for nonsurgical facial rejuvenation, using HA-based dermal fillers and botulinum toxin in order to improve injection skills, reduce complications, and optimize patient outcomes.
This program has been developed for dermatologists, plastic surgeons, ophthalmologists as well as other physicians, nurses and physician assistants who have an interest in gaining and/or increasing their knowledge and technical skill to perform facial aesthetic procedures with injectable agents.
Charles M. Boyd, MD, FACS
Rebecca Fitzgerald, MD, FAAD
Department of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, California
Shannon Humphrey, MD
Carruthers & Humphrey Cosmetic Medicine
Clinical Assistant Professor
Director of CME
University of British Columbia
Vancouver, BC, Canada
Steven G. Yoelin, MD
Newport Beach, California
Corey S. Maas, MD, FACS
The Maas Clinic
San Francisco, California
W. Tracy Hankins, MD
Hankins & Sohn Plastic Surgery Associates
CME Peer Reviewer
Victor B. Hatcher, PhD
Albert Einstein College of Medicine
Bronx, New York
Conflict of Interest StatementThe Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine and Montefiore Medical Center requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product or device company. Any presenter who has disclosed relationships that prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
The staff at Scientiae, LLC and the CCME staff at Albert Einstein College of Medicine and Montefiore Medical Center have no relevant conflicts of interest with commercial interests related directly or indirectly to this educational activity.
FACULTY AND PLANNING COMMITTEE DISCLOSURES:Charles M. Boyd, MD, MBA, FACS, has received fees for non-CME services from Allergan and Galderma. He has served as a member of a Speakers’ Bureau for Allergan and Galderma, and has performed contracted research for Galderma. Dr. Boyd has disclosed that he intends to reference unlabeled/unapproved uses of botulinum toxins and dermal fillers in his presentation.
Rebecca Fitzgerald, MD, has received fees for non-CME services from Allergan, Galderma, and Merz. She has received consulting fees from Allergan, Galderma, and Merz, and has served as a member of a Speakers’ Bureau for Allergan and Galderma. Dr. Fitzgerald has disclosed that she intends to reference unlabeled/unapproved uses of botulinum toxins and dermal fillers in her presentation.
Shannon Humphrey, MD, has received consulting fees from Abbvie, Actellion, Allergan, Amgen and Kythera, and has served on the speakers’ bureau for Allergan, Johnson & Johnson, GlaxoSmithKline and Merz.
Steven G. Yoelin, MD, has received fees for non-CME services from Allergan, Revance Therapeutics, Inc., and Bonti, Inc. He has received consulting fees from Allergan and Revance Therapeutics, Inc., and has served as a member of a Speakers’ Bureau for Allergan. He has also performed contracted research for Allergan, Revance Therapeutics, Inc., and Bonti, Inc. Dr. Yoelin has disclosed that he intends to reference unlabeled/unapproved uses of botulinum toxins and dermal fillers in his presentation.
Warren Tracy Hankins, MD, has received fees for non-CME services from Merz, Mentor, Neodyne Biosciences, Galderma, and Allergan. He has received consulting fees from Merz, Mentor, and Neodyne Biosciences, and has served as a member of a Speakers’ Bureau for Allergan and Galderma. Dr. Hankins has disclosed that he intends to reference unlabeled/unapproved uses of botulinum toxins and dermal fillers in his presentation.
Corey S. Maas, MD, FACS, has received consulting fees and has served as a member of a Speakers’ Bureau for Allergan, Galderma, Merz and Valeant. He has performed contracted research for Merz, Allergan and Syneron Candela, and has an ownership interest in Allergan.
Victor B. Hatcher, PhD** has indicated no conflict of interest.
Steve Ruskin, MD*, has indicated no conflict of interest.
**CME Program Reviewer
This CME activity discusses the off-label use of botulinum toxin, HA-based dermal fillers and calcium hydroxylapatite.
AMERICANS WITH DISABILITIES ACTAlbert Einstein College of Medicine and Scientiae, LLC, fully intends to comply with the legal requirements of the American with Disabilities Act. If any participant of this activity is in need of special accommodations, please contact PALETTE at least two weeks prior to the activity at 800-401-0291.
This activity is jointly sponsored by Albert Einstein College of Medicine and Scientiae, LLC.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and Scientiae, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT:
Albert Einstein College of Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
TERM OF APPROVAL:
December 31, 2016 through April 30, 2018
METHOD OF PARTICIPATION:
To receive a maximum of 2.5 AMA PRA Category 1 Credit(s)™ you should:
1. View all the video modules in this CME activity and evaluate the content presented
2. Complete and submit the CME posttest, evaluation form and registration form
To access activity, users will need:
Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher or any other W3C standards compliant browser. An HTML5 capable browser may be required for video or audio playback.
STATEMENT REGARDING PRIVACY AND SECURITY OF LEARNER RECORDS
All learner records (including test scores, attendance, evaluations, case studies, and other identified learning materials) shall be kept private and secure, whether in hardcopy or digital format, using a reasonable standard of diligence. In the event of a breach of learner privacy, learners shall be notified immediately. In addition, every effort shall be made to ensure HIPAA compliance of the personal medical privacy of healthcare patients, and study subjects.
Please click here to